Keytruda

(Pembrolizumab)

ApprovedMonoclonal antibody

Pembrolizumab is used to treat certain types of cancer, including melanoma and lung cancer, by helping the immune system recognize and attack cancer cells.[2] Keytruda is currently approved and in use across 337 indications[4].[1]

Keytruda is one of 2338 monoclonal antibody programs targeting Cervical Cancer. It is currently in Approved.

337

Indications

2,234

Total Trials

Active Trials

2,337

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Cervical CancerCompleted

Merkel Cell CarcinomaActive, not recruiting

Intestinal CancerCompleted

Richter SyndromeRecruiting

Mucosal MelanomaActive, not recruiting

Follicular LymphomaTerminated

MelanomaCompleted

Cutaneous Squamous Cell CarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaRecruiting

MeningiomaActive, not recruiting

Cervical CancerPhase 3

Completed

Merkel Cell CarcinomaPhase 3

Active, not recruiting

Intestinal CancerPhase 2

Completed

Richter SyndromePhase 2

Recruiting

Mucosal MelanomaPhase 2

Active, not recruiting

Follicular LymphomaPhase 2

Terminated

MelanomaPhase 3

Completed

Cutaneous Squamous Cell CarcinomaPhase 3

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

MeningiomaPhase 2

Active, not recruiting

Showing 10 of 336 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Approved

90 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

Spravato

WWim Janssens

Preclinical

2 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Non-Small Cell Lung Cancer

NCT02444741

Q4 2026

Phase 1Active, not recruiting

Intratumoral Injection

NCT03435952

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT05462236

Phase 1/2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT03153202

Phase 1/2Recruiting

Glioblastoma

NCT04977375

Phase 1Active, not recruiting

Neuroendocrine Cancer

NCT03582475

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer23 trials

Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT03087760·32 enrolled

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Completed·HHeat Biologics·Phase 1/2·NCT02439450·121 enrolled

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT03559049·25 enrolled

Show 20 more trials

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT03924869·448 enrolled

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT03325166·2 enrolled

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT05570825·30 enrolled

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Withdrawn·UUniversity of California, San Francisco·Phase 2·NCT04061590

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Completed· Incyte logo

Incyte·Phase 2·NCT03322540·154 enrolled

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05613413·36 enrolled

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05502237·1,021 enrolled

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT02444741·126 enrolled

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03976362·851 enrolled

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients

Terminated·OOslo University Hospital··NCT04557007·80 enrolled

Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02864394·425 enrolled

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

Active, not recruiting·UUNICANCER·Phase 3·NCT03774732·327 enrolled

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03875092·125 enrolled

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Terminated· GSK logo

GSK·Phase 2·NCT04581824·243 enrolled

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Unknown status·WWellmarker Bio·Phase 1·NCT05872867·54 enrolled

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03850444·262 enrolled

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT04042701·115 enrolled

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03302234·568 enrolled

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT03546361·24 enrolled

Pembrolizumab13 trials

Genetic Predictors of Benefit to Pembrolizumab

Terminated·—·Phase 2·NCT02710396·19 enrolled

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Terminated·—·Phase 2·NCT03823131·14 enrolled

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Completed·AAsha Nayak·Phase 1/2·NCT02834052·42 enrolled

Show 10 more trials

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Completed· Regeneron logo

Regeneron·Phase 1·NCT02680184·199 enrolled

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Terminated· Sanofi logo

Sanofi·Phase 2·NCT04524689·57 enrolled

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Terminated·NNektar Therapeutics·Phase 2/3·NCT04969861·1 enrolled

Special Combination of OBP-301 and Pembrolizumab

Completed·TToshihiko Doi·Phase 1·NCT03172819·22 enrolled

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Withdrawn·RRoswell Park Cancer Institute·Phase 2·NCT03935347

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Active, not recruiting·MMohammed Milhem·Phase 1/2·NCT05363631·55 enrolled

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT05059470·6 enrolled

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC

Active, not recruiting·GGeneos Therapeutics·Phase 1/2·NCT04251117·36 enrolled

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02954536·37 enrolled

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Not yet recruiting·—·Phase 2·NCT07465276·32 enrolled

Melanoma11 trials

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Completed·UUniversity of California, San Francisco·Phase 2·NCT03396952·27 enrolled

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Terminated· Amgen logo

Amgen·Phase 3·NCT02263508·713 enrolled

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

Completed·—··NCT03197636·40 enrolled

Show 8 more trials

Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma

Active, not recruiting·—·Phase 2·NCT03757689·63 enrolled

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Terminated·MMayo Clinic·Phase 1/2·NCT03325101·7 enrolled

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Unknown status·TTaizhou Hanzhong biomedical co. LTD·Phase 3·NCT05647954·350 enrolled

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03620019·25 enrolled

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT02130466·184 enrolled

Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab

Completed·—··NCT02909348·25 enrolled

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Active, not recruiting·MMelanoma Institute Australia·Phase 2·NCT04207086·21 enrolled

Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma

Withdrawn·DDiwakar Davar·Phase 2·NCT06030037

Breast Cancer9 trials

Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients

Recruiting·MMedical University of South Carolina·Phase 2·NCT06845319·43 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02819518·882 enrolled

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Completed·YYuan Yuan·Phase 2·NCT03025035·14 enrolled

Show 6 more trials

Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer

Recruiting·EEuropean Institute of Oncology·Phase 2·NCT03971045·46 enrolled

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Active, not recruiting·SStephen Shiao·Phase 1/2·NCT03366844·66 enrolled

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Unknown status·YYonsei University·Phase 2·NCT03492918·30 enrolled

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Withdrawn·NNorthwestern University·Phase 1·NCT05093387

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Completed·MMayo Clinic·Phase 1·NCT03012230·12 enrolled

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

Withdrawn·TThomas Jefferson University·Phase 1/2·NCT04418219

Lymphoma8 trials

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Completed·AALX Oncology Inc.·Phase 1·NCT03013218·174 enrolled

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04875195·66 enrolled

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03210662·17 enrolled

Show 5 more trials

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Completed·—·Phase 1/2·NCT02650999·12 enrolled

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02684292·304 enrolled

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Completed·II-Mab Biopharma US Limited·Phase 1·NCT03934814·98 enrolled

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Terminated·SStingthera, Inc.·Phase 1·NCT04609579·27 enrolled

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Not yet recruiting·UUniversity of Cologne·Phase 2·NCT06045195·40 enrolled

86 more indications

Prostate Cancer5 trials

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Withdrawn·OOHSU Knight Cancer Institute·Phase 2·NCT06528210

Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients

Unknown status·IIRCCS San Raffaele·Phase 2·NCT04565496·59 enrolled

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Not yet recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1·NCT07090369·20 enrolled

Show 2 more trials

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT03805594·43 enrolled

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT02312557·58 enrolled

Advanced Solid Tumors5 trials

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Active, not recruiting·DD2M Biotherapeutics Inc.·Phase 1·NCT06328673·160 enrolled

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03364049·33 enrolled

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

Recruiting· GSK logo

GSK·Phase 1·NCT06551142·590 enrolled

Show 2 more trials

Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02132754·116 enrolled

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Recruiting·OOncomatryx Biopharma S.L.·Phase 1·NCT05547321·150 enrolled

Glioblastoma4 trials

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03426891·21 enrolled

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Recruiting·—·Phase 1/2·NCT04977375·10 enrolled

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Active, not recruiting·MMayo Clinic·Phase 2·NCT03197506·52 enrolled

Show 1 more trial

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

Recruiting·MMedical University of Silesia·Phase 4·NCT05235737·36 enrolled

Triple-Negative Breast Cancer4 trials

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03599453·8 enrolled

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Not yet recruiting·—·Phase 2·NCT06407310·25 enrolled

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Completed·TTesaro, Inc.·Phase 1/2·NCT02657889·122 enrolled

Show 1 more trial

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Withdrawn·UUniversity of Washington·Phase 2·NCT03644589

Colorectal Cancer4 trials

Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05131919·25 enrolled

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02600949·117 enrolled

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT02713373·45 enrolled

Show 1 more trial

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Terminated·—·Phase 2·NCT03844750·6 enrolled

Renal Cell Carcinoma4 trials

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03142334·994 enrolled

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma

Recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT05024318·20 enrolled

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer··NCT04682587·481 enrolled

Show 1 more trial

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

Terminated·GGenenta Science·Phase 1/2·NCT06716853·10 enrolled

Small Cell Lung Cancer4 trials

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT03319940·269 enrolled

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03829332·623 enrolled

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03066778·453 enrolled

Show 1 more trial

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Completed·AAeglea Biotherapeutics·Phase 1/2·NCT03371979·68 enrolled

Hepatocellular Carcinoma4 trials

Pembrolizumab in Hepatocellular Carcinoma

Active, not recruiting·CCCTU·Phase 2·NCT03419481·30 enrolled

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02940496·15 enrolled

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT02702414·156 enrolled

Show 1 more trial

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Recruiting· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 1·NCT06600321·158 enrolled

Patients With Advanced Solid Tumors3 trials

FPT155 in Patients With Advanced Solid Tumors

Terminated·FFive Prime Therapeutics, Inc.·Phase 1·NCT04074759·80 enrolled

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Terminated·TTurnstone Biologics, Corp.·Phase 1·NCT05576077·31 enrolled

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Completed·SSyndax Pharmaceuticals·Phase 1·NCT02909452·30 enrolled

Metastatic Melanoma3 trials

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT02706353·34 enrolled

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Terminated·JJohn Rieth·Phase 1/2·NCT03957551·28 enrolled

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

Terminated·NNewLink Genetics Corporation·Phase 2·NCT03301636·21 enrolled

Lung Cancer3 trials

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT03846310·77 enrolled

Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)

Completed·—·N/A·NCT04793815·15 enrolled

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02079636·142 enrolled

Bladder Cancer3 trials

Pembrolizumab in Muscle-invasive Bladder Cancer

Active, not recruiting·MMatthew Galsky·Phase 2·NCT05406713·46 enrolled

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT03711032·1,397 enrolled

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04241185·520 enrolled

Head and Neck Cancer3 trials

Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy

Terminated·UUniversity of Chicago·Phase 2·NCT03463161·2 enrolled

A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

Withdrawn·UUniversity of Chicago·Phase 2·NCT03238638

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04847466·18 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04199104·511 enrolled

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04428151·408 enrolled

Endometrial Cancer2 trials

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Active, not recruiting·—·Phase 2·NCT03835819·18 enrolled

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03694834·3 enrolled

Multiple Myeloma2 trials

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

Withdrawn·EEmory University·Phase 2·NCT05204160

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02036502·77 enrolled

Advanced Solid Malignancies2 trials

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting·KKumquat Biosciences Inc.·Phase 1·NCT06994806·84 enrolled

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Active, not recruiting·TTreadwell Therapeutics, Inc·Phase 1/2·NCT04521413·170 enrolled

Head and Neck Squamous Cell Cancer2 trials

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04862455·14 enrolled

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04834349

Metastatic Colorectal Cancer2 trials

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Recruiting·AAUM Biosciences Pte Ltd·Phase 2·NCT05462236·120 enrolled

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT04854434·13 enrolled

Locally Advanced2 trials

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03414229·30 enrolled

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Recruiting·EEmory University·Phase 2·NCT06006013·21 enrolled

Advanced NSCLC2 trials

Phase II Trial of Continuation Therapy in Advanced NSCLC

Completed·—·Phase 2·NCT03083808·35 enrolled

Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03447678·65 enrolled

Primary Peritoneal Cancer2 trials

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT02853318·40 enrolled

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 2·NCT04375956·100 enrolled

Meningioma2 trials

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

Recruiting·—·Phase 2·NCT04659811·37 enrolled

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT03279692·26 enrolled

Urothelial Carcinoma2 trials

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02853305·1,010 enrolled

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Active, not recruiting·EEmory University·Phase 2·NCT04848519·6 enrolled

Metastatic Cancer2 trials

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

No longer available·NNational Institutes of Health Clinical Center (CC)··NCT04135092

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting·SSalubris Biotherapeutics Inc·Phase 1/2·NCT05620134·263 enrolled

Nasopharyngeal Carcinoma2 trials

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Terminated·AAtara Biotherapeutics·Phase 1/2·NCT03769467·12 enrolled

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Completed·SSeoul National University Hospital·Phase 2·NCT04227509·53 enrolled

Cervical Cancer2 trials

Pembrolizumab and Olaparib in Cervical Cancer Patients

Terminated·BBaptist Health South Florida·Phase 2·NCT04483544·8 enrolled

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03635567·617 enrolled

Acute Leukemia1 trial

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Withdrawn·—·Phase 1·NCT03605589

Cutaneous Squamous Cell Carcinoma1 trial

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Recruiting·QQueensland Health·Phase 2·NCT05025813·27 enrolled

Solid Tumors1 trial

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Active, not recruiting·VVyriad, Inc.·Phase 1/2·NCT03647163·33 enrolled

Malignancies1 trial

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Terminated·IIncyte Biosciences International Sàrl·Phase 1/2·NCT03277352·10 enrolled

Undifferentiated Pleomorphic Sarcoma1 trial

Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

Completed·RRoyal Marsden NHS Foundation Trust·Phase 1/2·NCT03123276·25 enrolled

Intratumoral Injection1 trial

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03435952·18 enrolled

Squamous Cell Carcinoma1 trial

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Terminated·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT02819752·3 enrolled

Uterine Cancer1 trial

Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

Completed·UUniversity Hospital, Ghent·Phase 2·NCT03192059·43 enrolled

Acute Myeloid Leukemia1 trial

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04214249·49 enrolled

Advanced or Metastatic Solid Tumors1 trial

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Recruiting· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 1·NCT06724016·292 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Terminated·PPierre Fabre Medicament·Phase 1·NCT04564417·33 enrolled

Advanced Urothelial Cancer1 trial

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT02335424·374 enrolled

Unresectable Biliary Tract Carcinoma1 trial

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04003636·1,069 enrolled

Laryngeal Squamous Cell Carcinoma1 trial

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

Completed·VVinita Takiar·Phase 1/2·NCT02759575·9 enrolled

Acral Lentiginous Melanoma1 trial

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Completed·—·Phase 2·NCT02875132·9 enrolled

Malignant Tumors1 trial

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Completed·KKling Biotherapeutics B.V.·Phase 1·NCT05501821·16 enrolled

Advanced/Metastatic Solid Tumors1 trial

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Completed· Incyte logo

Incyte·Phase 1·NCT02903914·260 enrolled

Metastasis1 trial

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Active, not recruiting·UUNICANCER·Phase 2·NCT04074096·10 enrolled

Laryngeal Cancer1 trial

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04030455·28 enrolled

Advanced Cancer1 trial

ATATcH Alternating Treatment Plans for Advanced Cancer

Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05358548·150 enrolled

Cancer1 trial

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting·PPresage Biosciences·Phase 1·NCT04541108·15 enrolled

Immunogenicity1 trial

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Recruiting·LLaboratorio Elea Phoenix S.A.·Phase 3·NCT05668650·174 enrolled

Pancreatic Adenocarcinoma1 trial

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

Withdrawn·NNYU Langone Health·Phase 4·NCT03891979

Uterine Carcinosarcoma1 trial

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05147558·40 enrolled

Carcinoma of Unknown Primary1 trial

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Terminated·HHoosier Cancer Research Network·Phase 2·NCT03396471·14 enrolled

Combination Therapy1 trial

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1·NCT06868732·288 enrolled

Chronic Lymphocytic Leukemia1 trial

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Active, not recruiting·JJoshua Brody·Phase 1/2·NCT03153202·23 enrolled

Advanced Malignancies1 trial

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting·IIncendia Therapeutics·Phase 1·NCT05753722·270 enrolled

Merkel Cell Carcinoma1 trial

Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma

Terminated·SStanford University·Phase 2·NCT03988647·1 enrolled

Pancreatic Cancer1 trial

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients

Completed·BBioLineRx, Ltd.·Phase 2·NCT02826486·80 enrolled

Ovarian Cancer1 trial

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Active, not recruiting·NNorth Eastern German Society of Gynaecological Oncology·Phase 2·NCT04575961·33 enrolled

Terminated·AAduro Biotech, Inc.·Phase 2·NCT03122548·5 enrolled

Ascites1 trial

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

Enrolling by invitation·—·N/A·NCT05745233·30 enrolled

Neoadjuvant Treatment1 trial

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

Completed·—·Phase 2·NCT03064490·35 enrolled

Metastatic NSCLC1 trial

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Recruiting·GGazi University··NCT07394062·400 enrolled

Refractory Tumor1 trial

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Not yet recruiting·MMohammed Milhem·Phase 1·NCT07404332·35 enrolled

Neuroendocrine Cancer1 trial

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT03582475·15 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting·UUniversity of Southampton·Phase 2·NCT05221645·65 enrolled

Prospective1 trial

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Unknown status·SSichuan University··NCT03373955·60 enrolled

Infusion1 trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Recruiting·IIsala·Phase 4·NCT06031233·679 enrolled

Chemotherapy1 trial

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04753879·38 enrolled

KRAS G12C1 trial

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04956640·540 enrolled

Head and Neck Carcinoma1 trial

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Active, not recruiting·RRTOG Foundation, Inc.·Phase 2·NCT03546582·86 enrolled

Treatment1 trial

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Active, not recruiting·VValo Therapeutics Oy·Phase 1·NCT05492682·15 enrolled

Basal Cell Carcinoma1 trial

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Completed·—·Phase 1·NCT04323202·13 enrolled

Gastric Cancer1 trial

FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT04768686·20 enrolled

Endometrial Carcinoma1 trial

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT05036681·9 enrolled

Adenocarcinoma1 trial

Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05268510·31 enrolled

Myelodysplastic Syndrome1 trial

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02936752·28 enrolled

Follicular Lymphoma1 trial

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Active, not recruiting·—·Phase 1·NCT03361852·20 enrolled

Central Nervous System Lymphoma1 trial

Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Unknown status·PProf. Dr. Matthias Preusser·Phase 2·NCT02779101·21 enrolled

Liver Cancer1 trial

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

Completed· Bayer logo

Bayer·Phase 2·NCT04696055·95 enrolled

Brachytherapy1 trial

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

Active, not recruiting·UUniversity of Cincinnati·Phase 1/2·NCT04340258·50 enrolled

Malignant Peripheral Nerve Sheath Tumor1 trial

A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery

Terminated·OOslo University Hospital·Phase 2·NCT02691026·8 enrolled

Anaplastic Meningioma1 trial

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Terminated·RRabin Medical Center·Phase 2·NCT03016091·18 enrolled

Immune Checkpoint Inhibition1 trial

REduced Frequency ImmuNE Checkpoint Inhibition in Cancers

Unknown status·UUniversity College, London·Phase 2·NCT04913025·160 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT03019588·94 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 4, 2014

Keytruda

BLA 125514

Sep 4, 2014

KEYTRUDA

BLA BLA125514

Sources

References

[1]
ClinicalTrials.gov — 2234 trial records for Pembrolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Keytruda drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pembrolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pembrolizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA 125514). U.S. Food & Drug Administration.
[6]
PubMed — 5 publications indexed for Pembrolizumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Merck & Co.

Key Publications[6]

Pembrolizumab Adjuvant Therapy in Resected Stage IIB/IIC Melanoma

LancetMay 22, 2023DOI: 10.1016/S0140-6736(23)00929-2

Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer

N Engl J MedAug 25, 2022DOI: 10.1056/NEJMoa2206594

Neoadjuvant Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

N Engl J MedMar 3, 2022DOI: 10.1056/NEJMoa2200181

Pembrolizumab in Microsatellite Instability-High Colorectal Cancer

N Engl J MedAug 26, 2021DOI: 10.1056/NEJMoa2107519

Five-Year Survival Outcomes With Pembrolizumab in Advanced NSCLC: KEYNOTE-024

J Clin OncolFeb 22, 2021DOI: 10.1200/JCO.20.03071

Keytruda

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer23 trials

Pembrolizumab13 trials

Melanoma11 trials

Breast Cancer9 trials

Lymphoma8 trials

Prostate Cancer5 trials

Advanced Solid Tumors5 trials

Glioblastoma4 trials

Triple-Negative Breast Cancer4 trials

Colorectal Cancer4 trials

Renal Cell Carcinoma4 trials

Small Cell Lung Cancer4 trials

Hepatocellular Carcinoma4 trials

Patients With Advanced Solid Tumors3 trials

Metastatic Melanoma3 trials

Lung Cancer3 trials

Bladder Cancer3 trials

Head and Neck Cancer3 trials

Head and Neck Squamous Cell Carcinoma2 trials

Endometrial Cancer2 trials

Multiple Myeloma2 trials

Advanced Solid Malignancies2 trials

Head and Neck Squamous Cell Cancer2 trials

Metastatic Colorectal Cancer2 trials

Locally Advanced2 trials

Advanced NSCLC2 trials

Primary Peritoneal Cancer2 trials

Meningioma2 trials

Urothelial Carcinoma2 trials

Metastatic Cancer2 trials

Nasopharyngeal Carcinoma2 trials

Cervical Cancer2 trials

Acute Leukemia1 trial

Cutaneous Squamous Cell Carcinoma1 trial

Solid Tumors1 trial

Malignancies1 trial

Undifferentiated Pleomorphic Sarcoma1 trial

Intratumoral Injection1 trial

Squamous Cell Carcinoma1 trial

Uterine Cancer1 trial

Acute Myeloid Leukemia1 trial

Advanced or Metastatic Solid Tumors1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Advanced Urothelial Cancer1 trial

Unresectable Biliary Tract Carcinoma1 trial

Laryngeal Squamous Cell Carcinoma1 trial

Acral Lentiginous Melanoma1 trial

Malignant Tumors1 trial

Advanced/Metastatic Solid Tumors1 trial

Metastasis1 trial

Laryngeal Cancer1 trial

Advanced Cancer1 trial

Cancer1 trial

Immunogenicity1 trial

Pancreatic Adenocarcinoma1 trial

Uterine Carcinosarcoma1 trial

Carcinoma of Unknown Primary1 trial

Combination Therapy1 trial

Chronic Lymphocytic Leukemia1 trial

Advanced Malignancies1 trial

Merkel Cell Carcinoma1 trial

Pancreatic Cancer1 trial

Ovarian Cancer1 trial

Relapsed/Refractory1 trial

Leukemia1 trial

Esophageal Cancer1 trial

Ascites1 trial

Neoadjuvant Treatment1 trial

Metastatic NSCLC1 trial

Refractory Tumor1 trial

Neuroendocrine Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Prospective1 trial